The settlement came just days before the case was set to go to trial
to decide damages, in which plaintiffs were expected to seek $2.4
billion. A judge had previously ruled Endo liable as a penalty for
failing to hand over evidence.
"We are pleased that after four-plus years of litigation that we
have been able to reach an agreement in principle with Endo, and are
grateful to the communities of northeast Tennessee for their support
in this landmark prosecution," said Gerard Stranch, a lawyer at
Branstetter, Stranch & Jennings, who represented the plaintiffs.
The deal must still be approved by some of the plaintiffs, Endo
said.
Endo shares had jumped about 25% on Tuesday after local government
officials revealed that the drugmaker had made a settlement offer.
The lawsuit, which was filed in 2017, is being pursued by nine
counties, 18 cities and a "Baby Doe" allegedly born with neonatal
abstinence syndrome, which is caused by withdrawal after in-utero
opioid exposure.
The plaintiffs alleged that Endo downplayed the risks of its
painkiller Opana ER, which was pulled from the market in 2017 due to
concerns about abuse. OxyContin maker Purdue Pharma and generic
opioid maker Mallinckrodt Plc were also named as defendants in the
case, but subsequently filed for bankruptcy, leaving Endo as the
only active defendant.
Chancellor E.G. Moody of the Circuit Court for Sullivan County, who
is overseeing the case, ruled in April that Endo and its lawyers
engaged in a "coordinated strategy" to withhold evidence, including
about opioid prescribers. He took the unusual step of entering
judgment of liability against the company as a sanction, leaving
only damages to be decided at trial.
[to top of second column] |
Nearly 500,000 people died from
opioid overdoses in the United States from 1999
to 2019, according to the U.S. Centers for
Disease Control and Prevention. The CDC last
week said provisional data showed that 2020 was
a record year for overall drug overdose deaths
with 93,331, up 29% from a year earlier.
The Tennessee case is among the more than 3,000 lawsuits, mostly by
local governments, accusing drugmakers of falsely promoting opioids
as safe and distributors and pharmacies of overlooking red flags
that drugs were being diverted to illegal channels. The defendants
have denied the claims.
U.S. state attorneys general on Wednesday unveiled a settlement
proposal in which leading drug distributors McKesson Corp, Cardinal
Health Inc and AmerisourceBergen Corp would pay a combined $21
billion, and drugmaker Johnson & Johnson would pay $5 billion, to
resolve most claims against them.
Endo is not part of that deal, and is currently defending itself
along with other drugmakers at trials in New York and California.
The company in 2019 settled opioid claims by two Ohio counties for
$10 million.
(Reporting By Brendan Pierson in New York, additional reporting by
Tom Hals and Nate Raymond; editing by Diane Craft)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |